Sofia, Bulgaria, 10 July 2026 - Provectus Capital Partners ("Provectus"), a private equity investor focused on Southeast Europe, has signed an agreement to partner with INVENIO Partners (“INVENIO”) and acquire a majority stake in a diversified private healthcare platform in Bulgaria, comprising the Haelan network of five outpatient medical centres, leading paediatric clinic First Children's Consultative Clinic, and two hospitals, Skin Systems and City Clinic St George (together, the "Group"). The transaction comprises a capital increase to support the Group's next phase of growth, alongside the partial sale of shares by the existing shareholders, led by INVENIO, a private equity investor with a strong track record of building regional champions across Bulgaria, Romania and Serbia. Following completion of the transaction, INVENIO will remain invested as a significant minority shareholder, with both investors partnering to support the Group’s development. The transaction is subject to customary regulatory approvals.
The Group brings together Bulgaria's largest outpatient network and two complementary hospitals, providing patients with access to a broad range of healthcare services across outpatient and inpatient settings. Together, these businesses employ approximately 650 professionals and generate more than €20 million in annual revenues.
The transaction marks Provectus' first investment in Bulgaria and reinforces the firm's long-term commitment to the healthcare sector across Southeast Europe. Building on the strong foundation established under INVENIO's ownership, Provectus will work alongside INVENIO and management to support the Group’s next stage of development. Going forward, the strategy will focus on accelerating the expansion of the Group's network through a combination of organic growth, targeted outpatient investments and selective acquisitions, further strengthening the Group’s businesses and broadening access to high-quality healthcare services across Bulgaria.
Marko Galić, Partner at Provectus Capital Partners, commented:
"This investment represents an important milestone for Provectus as our first investment in Bulgaria and reflects our conviction in the long-term potential of the country's private healthcare sector. We believe the Group combines a high-quality portfolio of healthcare assets with a clear opportunity to build Bulgaria's leading private healthcare provider.
Over the past several years, we have built deep expertise in executing buy-and-build strategies in private healthcare, successfully developing one of Croatia's leading healthcare groups. We believe many of the value creation levers that proved successful there are equally applicable to these businesses. We look forward to working alongside INVENIO and the management team to build on the strong foundation already established and execute its next phase of development.”
Tihomir Dyankov, CIO & Partner at INVENIO Partners, commented:
"We are extremely proud of the businesses we have built together with the management team over the past several years, and this transaction is a testament to their dedication and the hard work we have shared. In Provectus, we have found a partner whose deep experience in building private healthcare platforms makes it ideally placed to support the Group's next stage of development. We are confident that the combination of Provectus, INVENIO and our fellow shareholders, together with the steadfast leadership of our CEO Luka Chichov, will enable the Group to realise its full growth potential. We look forward to partnering with Provectus and continuing to support the businesses over the long term."
Luka Chichov, CEO of the Platform, commented:
"We are excited to welcome Provectus as our new shareholder and look forward to working alongside both shareholders as we continue executing our growth strategy. The combination of INVENIO's deep knowledge of the business and Provectus' proven experience in building private healthcare platforms creates a strong foundation for the next stage of our development. Our ambition remains unchanged: to continue expanding our network, investing in our clinical capabilities and broadening access to high-quality healthcare services for patients across Bulgaria."